Clinical Trials Sponsored by Cierra

Total 695 results

Cierra

Suspended

PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness (Paradigm IV)

Stroke | Migraine | Transient Ischemic Attack | Decompression Illness | PFO

Germany
Cierra

Suspended

PFx Closure System in Subjects With Cryptogenic Stroke,Transient Ischemic Attack,Migraine or Decompression Illness(PFO)

Patent Foramen Ovale

France, Germany, Belgium
Cierra

Completed

The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness

Foramen Ovale, Patent

Germany
Cierra

Unknown

Paradigm I Clinical Trial: Study of the PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemia Attack or Paradoxical Embolism

Patent Foramen Ovale

Germany
Sierra Oncology, Inc.

Completed

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Simplify 2)

Primary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)

United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
Sierra Oncology, Inc.

Completed

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada
Sierra Oncology, Inc.

Completed

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
Sierra Oncology, Inc.

Terminated

Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

United States
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
Sierra Oncology, Inc.

Completed

A Study of PNT2258 in Patients With Advanced Solid Tumors

Melanoma | Lymphoma | Cancer | Prostate Cancer

United States
Sierra Oncology, Inc.

Terminated

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States, France, Germany, Canada, Australia
Sierra Oncology, Inc.

Terminated

Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma

United States
Sierra Oncology, Inc.

Terminated

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

United States
Sierra Oncology, Inc.

Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
Cimera

Unknown

Chronic Obstructive Pulmonary Disease (COPD) History Assessment In SpaiN (CHAIN) (CHAIN)

COPD

Spain
Cimera

Unknown

CPASMA: Is There an Improvement in Asthma in Patients With Both Asthma and OSAS Treated With CPAP? (CPASMA)

Obstructive Sleep Apnea Syndrome | Asthma

Spain
Ceevra, Inc.

Completed

Using Virtual Reality (VR) Models for Preoperative Planning

Kidney Cancer | Renal Cell Carcinoma

United States
Ceevra, Inc.

Active, not recruiting

Using Virtual Reality (VR) Models for Robotic Prostatectomy

Prostate Cancer

United States
Ceevra, Inc.

Active, not recruiting

Using Virtual Reality (VR) Models for Robotic Prostatectomy - UNC

Prostate Cancer

United States
Pierre Fabre Medicament
Pierre Fabre Pharma GmbH

Completed

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

NSCLC

Germany
Pierre Fabre Medical Devices

Completed

Xerotic Dermatitis in Aged People

Itching Symptoms | Xerotic Dermatitis

France
Pierre Fabre Pharma GmbH
Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (BERING)

Melanoma Stage IV | Melanoma Stage III

Austria, Germany, Switzerland
Sierra Oncology LLC - a GSK company

Completed

A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Canada, Hungary, Israel, Spain, United States, Australia, Taiwan, Singapore, Germany, Italy, France, Belgium, New Zealand, Austria, United Kingdom, Denmark, Bulgaria, Poland, Czechia, Romania, Sweden
Sierra Oncology LLC - a GSK company

Terminated

PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)

Richter's Transformation

United States
Sierra Oncology LLC - a GSK company

Completed

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Primary Myelofibrosis (PMF) | Post-polycythemia Vera (Post-PV) Myelofibrosis | Postessential Thrombocythemia (Post-ET) Myelofibrosis

United States, Canada
Sierra Oncology LLC - a GSK company

Completed

A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer

Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)

United Kingdom
Sierra Oncology LLC - a GSK company

Terminated

Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

United States
Sierra Oncology LLC - a GSK company

Completed

Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin's

United States
Pierre Fabre Medicament

Recruiting

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (TavieSkin)

Metastatic Melanoma | Melanoma (Skin) | BRAF V600 Mutation

Portugal
Pierre Fabre Medicament

Active, not recruiting

A Study of a New Investigational Medicinal Product to Treat Patients With Advanced or Metastatic Solid Tumors (Ulysse)

Advanced or Metastatic Solid Tumors

France, Spain
Cidara Therapeutics Inc.

Completed

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension (STRIVE)

Mycoses | Candidemia | Fungemia | Fungal Infection | Invasive Candidiasis

United States, Spain, Belgium, Russian Federation, Greece, Bulgaria, Canada, Hungary, Italy, Romania
Pierre Fabre Medicament

Completed

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

Breast Cancer | Metastases

France, Ukraine, United Kingdom, Germany, Taiwan, Spain, Belarus, Belgium, Portugal, South Africa, Russian Federation, Austria, Italy, Argentina
Pierre Fabre Medicament

Completed

Efficacy and Safety Study of F373280

Atrial Fibrillation

Spain, Hungary, Italy, Poland, Czechia
Pierre Fabre Medicament

Completed

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

Breast Cancer
Cidara Therapeutics Inc.

Completed

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

Mycoses | Candidiasis, Vulvovaginal | Yeast Infection | Moniliasis, Vulvovaginal | Vaginitis, Monilial

United States
Cidara Therapeutics Inc.

Completed

An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects

Healthy

United States
Pierre Fabre Medicament

Completed

CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study

Recurrent Upper-Respiratory Tract Infections

Italy, Poland, Romania, Russian Federation, Lithuania
Pierre Fabre Medicament

Terminated

Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency Anaemia

Iron Deficiency Anemia

Bulgaria, Romania
Pierre Fabre Medicament

Completed

JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin (JASINT1)

Bladder Transitional Cell Carcinoma Stage IV

France
Pierre Fabre Medicament

Completed

Assessment of V0018 2.5 mg Effect on Craving

Healthy Highly Dependant Smokers

France
Pierre Fabre Medicament

Completed

Effect of F2695 on Functional Recovery After Ischemic Stroke (LIFE)

Ischemic Stroke

Spain, France, Switzerland, Germany, Sweden, Italy, Czech Republic, Portugal, Belgium, Hungary, Russian Federation
Pierre Fabre Dermatology

Completed

Study in Infants With Infantile Hemangioma to Compare Propranolol Gel to Placebo

Infantile Hemangioma

Spain, France, Poland
Pierre Fabre Medicament

Completed

Effect of V0251 in Acute Vertigo

Acute Vertigo

Spain, France, Germany, Czech Republic, Hungary
Pierre Fabre Medicament

Completed

Ibuprofen Lozenge in Acute Sore Throat Pain

Acute Sore Throat Pain

United Kingdom, Germany, Latvia, France
Pierre Fabre Dermatology

Completed

Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects

Healthy Volunteers

Germany
Pierre Fabre Medicament

Completed

Nicotine Patch Bioequivalence Study

Healthy Smokers

France
Pierre Fabre Medicament

Completed

Nicotine Patch - Multidose Bioequivalence Study

Healthy Smokers

France
Pierre Fabre Medicament

Completed

Pilot Pharmacokinetic Study of New Nicotine Lozenge Formulations

Healthy Smokers

France
Sierra Oncology LLC - a GSK company

Completed

PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)

Lymphoma, Diffuse Large B-Cell

United States, Puerto Rico
Sierra Oncology LLC - a GSK company

Completed

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

Advanced Solid Tumors

Spain, United Kingdom

Clinical Trials Sponsored by Cierra

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations